Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BA3182 |
Synonyms | |
Therapy Description |
BA3182 is a bispecific antibody targeting EpCAM and CD3E that redirects cytotoxic T-lymphocytes towards EpCAM-expressing tumor cells, potentially resulting in increased tumor cell killing (PMID: 38445633; NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BA3182 | BA-3182|BA 3182 | BA3182 is a bispecific antibody targeting EpCAM and CD3E that redirects cytotoxic T-lymphocytes towards EpCAM-expressing tumor cells, potentially resulting in increased tumor cell killing (PMID: 38445633; NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05808634 | Phase I | BA3182 | Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. | Recruiting | USA | 0 |